- Home
- PMM vs ITOS Comparison
PMM vs ITOS Comparison
Compare PMM & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMM
- ITOS
- Stock Information
- Founded
- PMM 1989
- ITOS 2011
- Country
- PMM United States
- ITOS United States
- Employees
- PMM N/A
- ITOS N/A
- Industry
- PMM Investment Managers
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PMM Finance
- ITOS Health Care
- Exchange
- PMM Nasdaq
- ITOS Nasdaq
- Market Cap
- PMM 284.9M
- ITOS 270.7M
- IPO Year
- PMM N/A
- ITOS 2020
- Fundamental
- Price
- PMM $6.34
- ITOS $7.41
- Analyst Decision
- PMM
- ITOS Strong Buy
- Analyst Count
- PMM 0
- ITOS 3
- Target Price
- PMM N/A
- ITOS $21.33
- AVG Volume (30 Days)
- PMM 118.3K
- ITOS 205.1K
- Earning Date
- PMM 01-01-0001
- ITOS 03-05-2025
- Dividend Yield
- PMM 4.68%
- ITOS N/A
- EPS Growth
- PMM N/A
- ITOS N/A
- EPS
- PMM 0.23
- ITOS N/A
- Revenue
- PMM N/A
- ITOS $35,000,000.00
- Revenue This Year
- PMM N/A
- ITOS $271.18
- Revenue Next Year
- PMM N/A
- ITOS N/A
- P/E Ratio
- PMM $26.52
- ITOS N/A
- Revenue Growth
- PMM N/A
- ITOS N/A
- 52 Week Low
- PMM $5.00
- ITOS $7.06
- 52 Week High
- PMM $6.42
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- PMM 61.45
- ITOS 45.45
- Support Level
- PMM $6.14
- ITOS $7.06
- Resistance Level
- PMM $6.42
- ITOS $7.61
- Average True Range (ATR)
- PMM 0.07
- ITOS 0.25
- MACD
- PMM 0.01
- ITOS 0.01
- Stochastic Oscillator
- PMM 71.43
- ITOS 40.23
About PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.